IL1B and autoimmune hepatitis: In fact, the results of this study showed that compared with the MSCs-treated group, sFgl2-MSCs more significantly protected the liver structure, significantly reduced inflammatory cell infiltration, lowered serum AST and ALT levels, and effectively reduced the pro-inflammatory factor IL-6 compared with the MSCs-treated group., IL-1β and TNF-α levels, while increasing the level of the anti-inflammatory factor IL-10, reducing systemic inflammation, these results suggest that sFgl2-MSCs have a more potent therapeutic effect on experimental AIH.